---
title: "Metabolic reprogramming in the immune microenvironment of Ewing sarcoma — article page summary"
id: "frontiers-in-immunology-8-metabolic-reprogramming-in-the-immune-microenvironment-of-ewing-sarcoma-from"
canonical_url: "https://medichelpline.com/clinical-feed/frontiers-in-immunology-8-metabolic-reprogramming-in-the-immune-microenvironment-of-ewing-sarcoma-from"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "Frontiers in Immunology"
source_url: "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1962178"
published_at: "2026-10-28T00:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Metabolic reprogramming in the immune microenvironment of Ewing sarcoma — article page summary
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/frontiers-in-immunology-8-metabolic-reprogramming-in-the-immune-microenvironment-of-ewing-sarcoma-from
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** Frontiers in Immunology
- **Source URL:** [Original Journal Publication](https://www.frontiersin.org/articles/10.3389/fimmu.2026.1962178)
- **Published At:** 2026-10-28T00:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The source page is a Frontiers in Immunology article listing but contained primarily site navigation and journal sections rather than the full manuscript text. - The page identified the item as a REVIEW article in Front. Immunol.; the visible partial citation reads “Front. Immunol., 28 Oc” but the source did not provide the complete publication date or full reference details. - The source did not include the article abstract, figures, methods, experimental cohorts, or outcome data; no clinical endpoints or quantitative results were available on the captured page. - The title on the source indicates the topic: metabolic reprogramming within the immune microenvironment of **Ewing sarcoma**, linking mechanisms to therapeutic strategies, but the page provided no mechanistic descriptions, pathways, or specific therapeutic approaches. - Investigators, author names, institutional affiliations, and trial identifiers were not present in the provided content; the source did not report these metadata elements. - Because the captured source lacked primary content, no statements about study design, sample size, dosing, in vitro versus in vivo models, or clinical trial phases can be extracted or summarized from it. - The main usable facts: journal (Frontiers in Immunology), article type (REVIEW), subject area (immune microenvironment and **metabolic reprogramming** in **Ewing sarcoma**). Further details require accessing the article full text through the publisher. - Unanswered, documentable questions from the page: what specific metabolic pathways are implicated, which immune cell types are reprogrammed, what therapeutic modalities are discussed, and what clinical evidence supports proposed strategies — none of these were reported on the captured page.
## Clinical Analysis & Structured Key Points
Frontiers | Metabolic reprogramming in the immune microenvironment of Ewing sarcoma: from mechanisms to therapeutic strategies REVIEW article Front. Immunol. , 28 October 2026 Sec. Cancer Immunity and Immunotherapy Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1962178 Published in Frontiers in Immunology Cancer Immunity and Immunotherapy 7 impact factor 11.3 citescore Part of a Research Topic Reprogramming tumor immunity: microenvironment, immune escape, and innovative immunotherapeutic strategies Submission open 13k views 9 articles Editor & Reviewers Edited by N B Natalia Belen Rumie Vittar Reviewed by J A Jonas Aakre Wik K C Kasturee Chakraborty Outline Figures and Tables Figure 1 View in article Figure 2 View in article Figure 3 View in article Figure 4 View in article Figure 5 View in article Table 1 Key metabolic reprogramming events driven by EWSR1-FLI1 in Ewing sarcoma. View in article Table 2 Metabolite-mediated immunosuppressive mechanisms. View in article Table 3 Representative therapeutic strategies at the metabolic–immune interface. View in article Table 4 Major translational challenges and proposed directions. View in article REVIEW article Front. Immunol. , 28 October 2026 Sec. Cancer Immunity and Immunotherapy Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1962178 Metabolic reprogramming in the immune microenvironment of Ewing sarcoma: from mechanisms to therapeutic strategies L T Lingyun Tang 1 H Z Haoling Zhou 2 J L Jia Liu 3 * 1. Department of Emergency Medicine, The Second Affiliated Hospital, University of South China, Hengyang, China 2. Department of Clinical Medicine, Changsha Medical University, Changsha, China 3. Department of Geriatrics, Shaoyang Central Hospital, Shaoyang, China See more Article metrics View details Abstract Ewing sarcoma is the second most common primary malignant bone tumor in children and adolescents, with the EWSR1-FLI1 fusion gene serving as its core driver event. Although multi-agent chemotherapy has achieved nearly 70% five-year survival in patients with localized disease, the prognosis for those with metastatic or relapsed/refractory disease remains poor, with long-term survival rates below 30%, and no substantial breakthrough has been made in first-line regimens over the past decade. Immune checkpoint inhibitors have revolutionized the treatment landscape for various adult solid tumors, but their efficacy in Ewing sarcoma—a typical “cold” tumor—is limited, owing to its low tumor mutational burden, sparse neoantigens, and highly immunosuppressive microenvironment. Recent studies suggest that EWSR1-FLI1 not only reshapes transcriptional programs but also functions as a metabolic “master switch, “ driving enhanced glycolysis, altered glutamine and tryptophan metabolism, and lipid metabolic remodeling. These metabolic alterations, in turn, produce lactate, kynurenine, lipid mediators, and local hypoxia, which suppress effector T cells and natural killer cells, induce regulatory T cells, and polarize macrophages toward a protumor phenotype, thereby forming a self-reinforcing causal chain between metabolism and immunity. This review systematically delineates this chain—from fusion-driven metabolic reprogramming, through metabolism-mediated immunosuppressive mechanisms, to intervention strategies targeting the metabolism–immunity interface. We focus on glycolysis inhibition, blockade of the tryptophan–AHR axis, lipid metabolism interventions, as well as novel surface targets (B7-H3, STEAP1, ENPP1, IL1RAP, MIF-CD74) for cell-based therapies and combination strategies of metabolic modulation with immunotherapy. We further analyze the practical obstacles to translating these strategies into clinical practice and, based on a critical synthesis of available evidence, Propose a metabolic–immune coupling model anchored on the active state of EWS-FLI1 to explain plasticity-driven resistance. This model provides a translational roadmap grounded in metabolic subtyping with the goal of “converting cold tumors to hot, “ offering a new framework for improving outcomes in Ewing sarcoma. 1 Introduction Ewing sarcoma is a highly aggressive small round cell sarcoma that predominantly arises in bone and soft tissue, and it is the second most common primary malignant bone tumor in children and adolescents, after osteosarcoma ( 1 – 3 ). Its incidence varies markedly across populations, being significantly higher in individuals of European descent than in East Asian and African populations, suggesting a genetic susceptibility background ( 3 – 5 ). Current standard therapy is based on interval-compressed chemotherapy alternating vincristine/doxorubicin/cyclophosphamide with ifosfamide/etoposide, combined with local surgery and radiotherapy ( 6 , 7 ). This regimen yields long-term survival rates approaching 70% for patients with localized disease; however, patients who present with metastases at diagnosis or who become relapsed/refractory have very limited responses, and their long-term survival has remained stalled at 20%–30% for decades ( 8 – 11 ). Systemic treatment options for metastatic and relapsed/refractory populations are scarce, and real-world long-term outcomes remain unsatisfactory ( 12 – 14 ). Part of this therapeutic dilemma stems from the immunologically “cold” nature of Ewing sarcoma. Unlike “hot” tumors such as melanoma and non-small cell lung cancer, Ewing sarcoma exhibits an extremely low tumor mutational burden, sparse neoantigens, insufficient infiltration of cytotoxic T cells and mature dendritic cells, and a predominance of macrophages with an immunosuppressive phenotype ( 11 ). Multiple immunoprofiling studies have shown that M2-type macrophages constitute the highest proportion of tumor-infiltrating leukocytes and are associated with worse event-free survival, while immune checkpoint blockade alone rarely elicits durable responses in this disease. The molecular cornerstone of Ewing sarcoma is the EWSR1-FLI1 fusion gene generated by the chromosomal translocation t(11;22)(q24; q12) ( 15 ). Approximately 85% of cases are driven by this fusion, with the remainder harboring fusions of EWSR1 with other ETS family members ( 16 – 18 ). As an aberrant transcription factor, EWSR1-FLI1 binds to GGAA microsatellites in the genome and induces neo-enhancers, extensively rewiring transcriptional programs. In recent years, it has become increasingly recognized that its role extends far beyond transcription: it simultaneously acts as a metabolic “master switch” that, through reprogramming glucose, amino acid, and lipid metabolism, not only meets the biosynthetic demands of the tumor but also actively shapes a microenvironment that is hostile to antitumor immunity ( 2 ). This review follows the main axis of “driver gene → metabolic reprogramming → immunosuppression → targeted intervention → obstacles and translation, “ and systematically examines metabolic reprogramming within the immune microenvironment of Ewing sarcoma and the therapeutic opportunities it presents. 2 EWSR1-FLI1: the master switch of metabolic reprogramming 2.1 Fusion gene, GGAA enhancers, and chromatin remodeling Through its FLI1 moiety, EWSR1-FLI1 recognizes GGAA motifs and acts as a pioneer factor at GGAA microsatellite repeats, opening closed chromatin and de novo establishing tumor-specific enhancers ( 19 – 21 ). The EWSR1 portion contains a low-complexity prion-like domain that recruits the BAF (SWI/SNF) chromatin remodeling complex to these microsatellites, driving transcription of target genes ( 22 , 23 ). Microsatellite repeat length varies among individuals and populations, thereby influencing enhancer activity and susceptibility, which partially accounts for the ethnic differences in incidence ( 24 ). Polycomb proteins such as RING1B assist in recruiting EWSR1-FLI1 to critical enhancers, further stabilizing its transcriptional regulatory network ( 25 , 26 , 40 ). It is important to emphasize that EWSR1-FLI1 expression and activity are not homogeneous across cells or within tumors, but rather fluctuate reversibly between a “high-activity” proliferative state and a “low-activity” migratory/invasive state; this plasticity is an intrinsic feature of its oncogenic potential and lays the groundwork for metabolic and immune heterogeneity ( 27 , 28 ). 2.2 Reprogramming of glucose metabolism Similar to most tumors, Ewing sarcoma exhibits classic aerobic glycolysis (the Warburg effect), preferentially converting glucose to lactate even in the presence of abundant oxygen ( 29 – 32 ). EWSR1-FLI1 upregulates key glycolytic nodes, including hexokinase, glucose transporters, and lactate dehydrogenase A (LDHA), providing tumor cells with carbon skeletons and reducing equivalents required for rapid proliferation; LDHA inhibition reduces glycolytic flux and suppresses tumor growth in multiple preclinical models of Ewing sarcoma ( 33 – 35 ). Dual targeting of energy metabolism by combining 2-deoxyglucose with metformin induces apoptosis and reduces stem-like properties across a panel of Ewing sarcoma cell lines ( 36 ). These findings were obtained exclusively in two-dimensional monolayer culture, and we do not regard them as evidence of activity against tumor growth. Solid tumors develop internal hypoxia, nutrient depletion and restricted drug penetration, all of which drive phenotypic adaptation and shift drug sensitivity relative to monolayer culture; the combination has not been evaluated in vivo in Ewing sarcoma. Because both agents act on core energy-metabolic machinery that also operates in normal proliferating tissue, the risk of additive adverse effects is a further reason to confine interpretation to the in vitro setting. Mitochondrion-directed interventions have separately been proposed as a complementary strategy across tumor types ( 37 ). Melatonin has been reported to exert cytotoxicity against Ewing sarcoma cells by inhibiting the Warburg effect ( 38 ). One direct consequence of glycolysis is the massive efflux of lactate and protons, leading to microenvironmental acidification, which will be detailed in the immunosuppression section. 2.3 Reprogramming of amino acid metabolism EWSR1-FLI1 positively regulates serine-glycine biosynthesis and exogenous serine uptake, providing precursors for nucleotide synthesis and one-carbon metabolism, thereby rendering the tumor dependent on the serine pathway and creating a potential metabolic vulnerability ( 34 , 35 , 39 ). In parallel, glutamine is converted by glutaminase (GLS) into glutamate and enters the tricarboxylic acid (TCA) cycle, supporting macromolecular synthesis and redox balance, representing another hub of tumor metabolism ( 41 – 43 ). Glutamine entry is itself transporter-dependent, and this is where the Ewing-specific layer lies: EWS-FLI1 binds a regulatory element within SLC1A5 (ASCT2) and positively regulates its expression, and a signature comprising SLC1A5 together with PHGDH, PSAT1, PSPH, SHMT2, MTHFD2 and MTHFD1L stratifies patients with Ewing sarcoma into distinct overall-survival groups ( 34 ). Because activated effector T cells depend on the same transporter family for glutamine uptake, tumor-cell overexpression of SLC1A5 supplies a concrete molecular basis for nutrient competition at the tumor–immune interface rather than a generic appeal to “glutamine addiction” (Section 3.4). Tryptophan (Trp) metabolism constitutes a third critical axis: indoleamine 2, 3-dioxygenase 1 (IDO1) and tryptophan 2, 3-dioxygenase (TDO2) catalyze the conversion of tryptophan to kynurenine, both depleting local tryptophan and producing immunomodulatory kynurenine; its immunological consequences will be expanded in Chapter 3. Overall, amino acid metabolic remodeling simultaneously serves tumor biosynthesis and immune evasion. 2.4 Reprogramming of lipid metabolism Lipid metabolism is also markedly altered in Ewing sarcoma. Key enzymes of de novo fatty acid synthesis, such as fatty acid synthase (FASN) and acetyl-CoA carboxylase (ACC), are upregulated, providing substrates for membrane synthesis and signaling lipids, while altered regulation of fatty acid oxidation affects energy supply and redox status ( 44 – 46 ). Studies on nutritional and metabolic adaptation further reveal that Ewing sarcoma possesses flexible capabilities for lipid and energy acquisition under different nutrient conditions and can be targeted by metabolic reprogramming-modulating agents ( 47 – 49 ). Beyond de novo synthesis, Ewing-specific data define several further layers, which we set out here because this section was previously too brief to support the immunological claims made later. First, membrane-lipid remodeling. The core regulatory circuitry operating under EWS-FLI1 (KLF15, TCF4, NKX2-2) directly co-occupies the promoters of FASN, SCD and ACLY, of the sphingolipid enzymes SPTLC1, DEGS1 and UGCG, and of the glycerophospholipid enzyme LPIN2; silencing any of these factors shifts the measured lipidome, with glycerophospholipid and sphingolipid metabolism the two most strongly affected pathways, and the corresponding enzyme inhibitors are cytotoxic to Ewing sarcoma cells ( 202 ). Lipid metabolism in this disease is therefore not a passive anabolic requirement but a transcriptionally specified programme. Second, glycerophospholipid biosynthesis as a resistance node: loss of SLFN11 redirects flux toward glycerophospholipid synthesis and drives resistance to DNA-damaging agents, and co-targeting DNA damage together with lipid biosynthesis produces synergistic antitumor effects, identifying a metabolic vulnerability that is created rather than merely accompanied by chemoresistance ( 203 ). Third, lipid storage and uptake. Triglyceride esterification and lipid-droplet turnover determine how much free polyunsaturated fatty acid is available for membrane incorporation, and therefore set the threshold at which lipid peroxidation becomes lethal; in Ewing sarcoma this threshold is actively defended, for example through SETD8-dependent signaling, whose loss sensitizes cells to both apoptosis and ferroptosis ( 204 ). Fourth, and connecting these to immunity, the lipid species that sustain tumor membranes are the same species taken up by infiltrating CD8+ T cells through CD36, where they drive peroxidation and ferroptotic loss of effector function (Section 3.5). The asymmetry is the point: the tumor invests in ferroptosis defense while the effector compartment does not. Lipid mediators (e.g., prostaglandin E2) and the transfer of tumor-derived lipids to immune cells constitute the material basis through which lipid metabolism influences immunity ( 50 , 51 )( Figure 1 ; Table 1 ). Figure 1 EWSR1-FLI1-driven metabolic reprogramming in Ewing sarcoma. The t(11;22) translocation generates the EWSR1-FLI1 fusion transcription factor, which binds GGAA microsatellites and remodels chromatin to act as a metabolic master switch, coordinately reprogramming glucose, amino-acid, and lipid metabolism and thereby fueling proliferation, invasion, and an immunosuppressive microenvironment. The metabolic-plasticity band is shown below the outcome row so that no connector crosses it. Superscript charges are rendered as plain characters (H+) to avoid glyph substitution, arrow weight has been increased, and font sizes enlarged. ACC, acetyl-CoA carboxylase; BAF, BRG1/BRM-associated factor (SWI/SNF) chromatin-remodeling complex; FASN, fatty-acid synthase; GGAA, (GGAA)n microsatellite; GLS, glutaminase; GLUT1, glucose transporter 1; HK2, hexokinase 2; IDO1, indoleamine 2, 3-dioxygenase 1; α-KG, α-ketoglutarate; LDHA, lactate dehydrogenase A; OXPHOS, oxidative phosphorylation; PGE2, prostaglandin E2; SLC1A5, solute carrier family 1 member 5 (ASCT2); TDO2, tryptophan 2, 3-dioxygenase 2; TME, tumor microenvironment; Trp, tryptophan. Table 1 Pathway Key change Representative nodes Functional consequence Glycolysis Aerobic glycolysis ↑ LDHA, HK2, GLUT1 Lactate/acidosis; biosynthetic precursors Glutamine Glutaminolysis ↑ GLS, glutamine import; SLC1A5 (ASCT2) TCA anaplerosis; redox balance Serine/1-C Serine synthesis ↑ PHGDH, SHMT Nucleotide & methyl-donor supply Tryptophan Kynurenine pathway ↑ (Trp, tryptophan) IDO1, TDO2 Immunomodulatory kynurenine Lipid De novo synthesis ↑; glycerophospholipid and sphingolipid remodelling ↑ FASN, ACC; SCD, ACLY, LPIN2, SPTLC1 Membranes; signaling lipids Key metabolic reprogramming events driven by EWSR1-FLI1 in Ewing sarcoma. 2.5 Metabolic plasticity and epigenetic–metabolic coupling Metabolism in Ewing sarcoma is not unidirectionally locked into glycolysis; rather, it retains plasticity that allows parallel operation of glycolysis and oxidative phosphorylation, enabling flexible switching under nutritional fluctuation and therapeutic pressure, and there exists a “programmed” nutrient allocation between the tumor and its microenvironment ( 52 ). More importantly, metabolic intermediates directly feed back into the epigenetic layer: acetyl-CoA supplies histone acetylation, α-ketoglutarate modulates demethylase activity, and lactate alters gene expression through histone lactylation (see Section 3.2 for details). Acetylation deserves particular emphasis in this disease, since it is the modification most tightly bound to the fusion itself. The de novo enhancers that EWSR1-FLI1 establishes at GGAA microsatellites are defined by high H3K27 acetylation, and this enhancer signature is one of the features that most sharply distinguishes Ewing sarcoma from other small round cell tumors ( 23 ). The acetyl-CoA pool that supplies H3K27ac is generated by glycolytic and lipogenic flux through ACLY, ACC and FASN (Sections 2.2 and 2.4), which places nutrient availability upstream of fusion-driven enhancer activity rather than only downstream of it. This yields a testable prediction: metabolic restriction that lowers the nucleocytosolic acetyl-CoA pool should attenuate H3K27ac at GGAA enhancers and soften the EWSR1-FLI1 transcriptional output, moving cells toward the low-activity state. We present this explicitly as a hypothesis, because acetyl-CoA-dependent modulation of GGAA-enhancer acetylation has not been directly demonstrated in Ewing sarcoma; if it holds, it would mean that metabolic intervention and epigenetic intervention are acting on the same node from opposite directions. This metabolic–epigenetic coupling enables the tumor to “write” nutritional status into transcriptional programs, and it interweaves with the switching between high- and low-activity states of EWSR1-FLI1, forming a common basis for adaptive resistance and immune heterogeneity ( 27 , 28 ). 2.6 Critical summary: re-examining the causality of the “master switch” The “master switch” is a useful narrative, but it may imply a linear, homogeneous causality that is not yet supported by the data. At least three caveats should be noted. First, most of the causal evidence for the “metabolism → immunosuppression” mechanisms cited herein derives from models such as melanoma and colorectal cancer; in Ewing sarcoma, these are mostly correlative or extrapolative. Studies that directly manipulate the chain “EWS-FLI1 → a given metabolite → a given immune cell” within Ewing sarcoma models remain few (common mechanistic parallels have been elucidated in other tumor systems, as detailed in Chapter 3). Second, EWS-FLI1 activity is not constant but fluctuates between proliferative and invasive states ( 27 , 28 ); therefore, the notion that “the fusion gene uniformly drives glycolysis” cannot hold neatly. Indeed, spatial data from paired biopsies in SARC028 show that the immune-evasive phenotype is specifically enriched in tumor subpopulations with high EWSR1-FLI1 target gene expression and low HLA-I (SARC028 spatial data, see Section 5.1.1)—in other words, the immune-metabolic phenotype is “activity-state-dependent” rather than “fusion-constant.” Third, the relationship between hypoxia and EWSR1-FLI1 is bidirectional, and we have taken car
## Related Clinical Research

- [Metformin use and incident breast cancer risk: time-bias–aware meta-analysis and limits for imegli](https://medichelpline.com/clinical-feed/medrxiv-8-metformin-use-and-the-risk-of-incident-breast-cancer-a-systematic-review-and.md)
- [YTHDF2 promotes cutaneous melanoma progression via m6A-dependent HMOX1 regulation of ferroptosis](https://medichelpline.com/clinical-feed/pubmed-42848283.md) (DOI: 10.1007/s12032-026-03427-y)
- [Targeting VISTA for Skin Cancer Immunotherapy: Source Article Not Available](https://medichelpline.com/clinical-feed/frontiers-in-immunology-17-targeting-vista-as-a-novel-immunotherapy-for-skin-cancer.md)
- [Lonidamine plus devimistat produces synergistic antitumor effects in NSCLC by disrupting cellular](https://medichelpline.com/clinical-feed/pubmed-42627059.md) (DOI: 10.3892/or.2026.9184)
- [Fecal Microbiome and Metabolome During Immunotherapy-Based Total Neoadjuvant Therapy in Rectal Can](https://medichelpline.com/clinical-feed/frontiers-in-immunology-11-commentary-fecal-microbiome-and-metabolome-dynamics-during-immunotherapy-based.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.